REG - Indivior PLC - Result of General Meeting

IndiviorAnnouncement

23/05/2024 13:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240523:nRSW7023Pa&default-theme=true

RNS Number : 7023P  Indivior PLC  23 May 2024

Indivior PLC (the 'Company')

Result of General Meeting

May 23, 2024

The Company announces the voting result of its General Meeting, held earlier
today at the offices of Freshfields Bruckhaus Deringer, 100 Bishopsgate,
London EC2P 2SR.

The resolution set out in the Notice of Meeting circulated to shareholders and
published on May 3, 2024 was duly passed by shareholders by way of a poll.

The voting result, incorporating proxy votes lodged in advance of the General
Meeting, is set out below and will be made available on the Company's website
at http://www.indivior.com/en/investors/shareholder-information
(http://www.indivior.com/en/investors/shareholder-information) .

 

 RESOLUTION                                                                    VOTES       %      VOTES       %      VOTES       % of ISC VOTED(1)    VOTES

FOR
AGAINST
TOTAL
WITHHELD(2)
 To approve the transfer of the Company's category of equity share listing on  86,261,468  96.94  2,718,492   3.06%  88,979,960  65.86                9,491
 the London Stock Exchange plc from a Premium Listing to a Standard Listing

 

Graham Hetherington, Chair, said:

'We are pleased with the strong support received from shareholders at today's
General Meeting to enable Indivior to move its primary listing to the Nasdaq
Stock Market. We believe that this move will better align with the Group's
current and future growth opportunities, attract more U.S. investors and
analysts, allow for inclusion in U.S. indices over time and better reflect the
growing proportion of our investors that are based in the U.S.

We expect the transfer of the primary listing will become effective on
Thursday June 27, 2024. The Board intends to maintain Indivior's U.K. listing
as a secondary listing following the transfer for as long as it is considered
to be in the best interests of Indivior and Indivior shareholders as a whole.'

 

Notes:

 

1.         As at the close of business on May 21, 2024, the total
number of ordinary shares of US$0.50 eligible to be voted at the GM was
135,096,376.  Therefore, the total voting rights in the Company as at that
time was 135,096,376.

2.         A vote withheld is not a vote in law and is not counted in
the calculation of the votes for or against a resolution.

A copy of the resolution will be submitted to the National Storage Mechanism
and will be available to view at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) in due course.

Computershare Investor Services PLC acted as scrutineer of the poll on the
resolution.

 

Key Contacts:

Jason Thompson

VP, Investor Relations

+1 804-402-7123 or jason.thompson@indivior.com
(mailto:jason.thompson@indivior.com)

 

Tim Owens

Director, Investor Relations

+1 804-263-3978 or timothy.owens@indivior.com
(mailto:timothy.owens@indivior.com)

 

Kathryn Hudson

Company Secretary

+44 (0)1753 423940 or kathryn.hudson@indivior.com
(mailto:kathryn.hudson@indivior.com)

 

About Indivior

Indivior is a global pharmaceutical company working to help change patients'
lives by developing medicines to treat substance use disorders (SUD) and
serious mental illnesses. Our vision is that all patients around the world
will have access to evidence-based treatment for the chronic conditions and
co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from
a global human crisis to a recognized and treated chronic disease. Building on
its global portfolio of OUD treatments, Indivior has a pipeline of product
candidates designed to both expand on its heritage in this category and
potentially address other chronic conditions and co-occurring disorders of
SUD, including alcohol use disorder and cannabis use disorder. Headquartered
in the United States in Richmond, VA, Indivior employs over 1,100 individuals
globally and its portfolio of products is available in 37 countries worldwide.
Visit www.indivior.com
(https://indiviorplc-my.sharepoint.com/personal/timothy_owens_indivior_com/Documents/Desktop/a.%20Quarters/j.%20Q124/Calendar%20invite/www.indivior.com?xsdata=MDV8MDJ8amFzb24udGhvbXBzb25ASW5kaXZpb3IuY29tfGQ4N2QwYmU2M2FmNTQzYTUyYTI2MDhkYzZhYWEzOWI2fGJlZDUyMTkxNDg5NDQyOTk5ZGI5NDhlNGZiMjk2NDZlfDF8MHw2Mzg1MDI1MjY1NDIwMTM3MDN8VW5rbm93bnxUV0ZwYkdac2IzZDhleUpXSWpvaU1DNHdMakF3TURBaUxDSlFJam9pVjJsdU16SWlMQ0pCVGlJNklrMWhhV3dpTENKWFZDSTZNbjA9fDB8fHw%3d&sdata=M0FsUHZ1L1F5bFZ6dkJLM2RDdjJGbEJ6M0gxczNyZlhaWnR1MXJZMlVFQT0%3d)
 to learn more. Connect with Indivior on LinkedIn by
visiting www.linkedin.com/ company/indivior
(https://indiviorplc-my.sharepoint.com/personal/timothy_owens_indivior_com/Documents/Desktop/a.%20Quarters/j.%20Q124/Calendar%20invite/www.linkedin.com/%20company/indivior?xsdata=MDV8MDJ8amFzb24udGhvbXBzb25ASW5kaXZpb3IuY29tfGQ4N2QwYmU2M2FmNTQzYTUyYTI2MDhkYzZhYWEzOWI2fGJlZDUyMTkxNDg5NDQyOTk5ZGI5NDhlNGZiMjk2NDZlfDF8MHw2Mzg1MDI1MjY1NDIwMjY3Mzl8VW5rbm93bnxUV0ZwYkdac2IzZDhleUpXSWpvaU1DNHdMakF3TURBaUxDSlFJam9pVjJsdU16SWlMQ0pCVGlJNklrMWhhV3dpTENKWFZDSTZNbjA9fDB8fHw%3d&sdata=OHIremJVOGFVYXBDOUtpeWlqUmhCdm9FbG5lNFVRNFlmWFpybGtFNk5vcz0%3d)
.

Important Cautionary Note Regarding Forward-Looking Statements

This announcement contains certain statements that are forward-looking.
Forward-looking statements include, among other things, statements regarding
our intention to transfer our primary listing to Nasdaq while maintaining a
secondary listing in the U.K., and the expected timing and potential benefits
of such transfer; expected future growth; and other statements containing the
words "believe," "anticipate," "plan," "expect," "intend," "estimate,"
"forecast," "strategy," "target," "guidance," "outlook," "potential,"
"project," "priority," "may," "will," "should," "would," "could," "can,"
"outlook," "guidance," the negatives thereof, and variations thereon and
similar expressions. By their nature, forward-looking statements involve risks
and uncertainties as they relate to events or circumstances that may or may
not occur in the future.

Actual results may differ materially from those expressed or implied in such
statements because they relate to future events. Various factors may cause
differences between Indivior's expectations and actual results, including,
among others, the material risks described in the most recent Indivior PLC
Annual Report and in subsequent releases; the substantial litigation and
ongoing investigations to which we are or may become a party; our reliance on
third parties to manufacture commercial supplies of most of our products,
conduct our clinical trials and at times to collaborate on products in our
pipeline; our ability to comply with legal and regulatory settlements,
healthcare laws and regulations, requirements imposed by regulatory agencies
and payment and reporting obligations under government pricing programs; risks
related to the manufacture and distribution of our products, most of which
contain controlled substances; market acceptance of our products as well as
our ability to commercialize our products and compete with other market
participants; competition; the uncertainties related to the development of new
products, including through acquisitions, and the related regulatory approval
process; our dependence on third-party payors for the reimbursement of our
products and the increasing focus on pricing and competition in our industry;
unintended side effects caused by the clinical study or commercial use of our
products; our ability to successfully execute acquisitions, partnerships,
joint ventures, dispositions or other strategic acquisitions; our ability to
protect our intellectual property rights and the substantial cost of
litigation or other proceedings related to intellectual property rights; the
risks related to product liability claims or product recalls; the significant
amount of laws and regulations that we are subject to, including due to the
international nature of our business; macroeconomic trends and other global
developments such as armed conflicts and pandemics; the terms of our debt
instruments, changes in our credit ratings and our ability to service our
indebtedness and other obligations as they come due; changes in applicable tax
rate or tax rules, regulations or interpretations and our ability to realize
our deferred tax assets; and volatility in our share price due to factors
unrelated to our operating performance or that may result from the potential
move of our primary listing to the U.S.

Forward-looking statements speak only as of the date that they are made and
should be regarded solely as our current plans, estimates and beliefs. Except
as required by law, we do not undertake and specifically decline any
obligation to update, republish or revise forward-looking statements to
reflect future events or circumstances or to reflect the occurrences of
unanticipated events.

Indivior PLC's Legal Entity Identifier code is 213800V3NCQTY7IED471.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORMZGZKZFVGDZM